Company profile: DiaCarta
1.1 - Company Overview
Company description
- Provider of precision molecular diagnostics, including CE/IVD-marked KRAS detection, for cancer screening, monitoring, and therapy guidance. Offerings include RadTox for real-time cfDNA treatment response; ColoScape for colorectal screening and FIT-positive triage via plasma cfDNA changes; QClamp for sensitive ctDNA mutation detection; OptiSeq Colorectal Cancer NGS Panel for actionable mutations; Oncuria urine biomarkers; and custom mini-MRD panels.
Products and services
- ColoScape™: Plasma-based assay for colorectal cancer screening and FIT-positive triage, detecting genetic and epigenetic changes in plasma cell-free DNA
- OptiSeq™ Colorectal Cancer NGS Panel: NGS-based assay that detects actionable mutations in colorectal cancer and delivers targeted therapy information for treatment selection
- QClamp®: Ultra-sensitive assay that detects single gene mutations in circulating tumor DNA, useful for early cancer detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DiaCarta
IONIQ Sciences
HQ: United States
Website
- Description: Provider of solutions for early detection of multiple cancers to improve survivability and reduce healthcare costs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IONIQ Sciences company profile →
NovaScan
HQ: United States
Website
- Description: Provider of cancer detection and surgical decision-support technologies based on Cole frequency measurements, including MarginScan for tissue-sparing skin cancer excisions with margin confirmation without histology; nsCanary for real-time biopsy assessment (pancreatic, biliary, lung); Predictive Technology to assess presence, aggressiveness, and metastasis likelihood; and an Electrical Mammogram detecting breast cancer without radiation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaScan company profile →
OncoVista Innovative Therapies
HQ: United States
Website
- Description: Provider of anticancer therapy development utilizing tumor-associated biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoVista Innovative Therapies company profile →
Ratio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-phase radiopharmaceuticals for solid tumors, with the Trillium platform for pharmacokinetic modulation to improve tumor-targeted delivery, the Macropa chelator for actinium-225 conjugation, FAP-targeted therapies including a PET diagnostic, and a Granzyme B PET imaging agent to monitor immune response in cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ratio Therapeutics company profile →
Indi
HQ: United States
Website
- Description: Provider of diagnostic products leveraging emerging technologies to help physicians and patients diagnose and manage complex diseases, such as cancer, diabetes, and Alzheimer’s, through non-invasive blood tests that monitor tens to hundreds of disease markers simultaneously.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Indi company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DiaCarta
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DiaCarta
2.2 - Growth funds investing in similar companies to DiaCarta
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DiaCarta
4.2 - Public trading comparable groups for DiaCarta
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →